SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 14, 2003
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | 94-3267443 | |
| (Commission file Number) | (IRS Employer ID Number) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina | 27615 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
Item 5. Other Events and Regulation FD Disclosure
On November 14, 2003, Salix Pharmaceuticals, Ltd. (the “Registrant”) issued a press release announcing that the Registrant will be incorporated into the NASDAQ Biotechnology Index® (NASDAQ:NBI), effective November 24, 2003. A copy of this press release is attached.
Item 7. Financial Statements and Exhibits.
| (c) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Press release dated November 14, 2003, announcing that the Registrant will be incorporated into the NASDAQ Biotechnology Index® (NASDAQ:NBI), effective November 24, 2003. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
| ||||||||
| Date: | November 14, 2003 | By: | /s/ Adam C. Derbyshire | |||||
Adam C. Derbyshire Senior Vice President and Chief Financial Officer | ||||||||
